ReviewCurrent oncology (Toronto, Ont.)2022

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab.

Charlie Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.